Dolnoslaskie Centrum Onkologii Pulmonologii I Hematologii

The research program at Dolnoslaskie Centrum Onkologii Pulmonologii I Hematologii is strongly focused on neoplasms, with many studies exploring new ways to treat advanced and difficult-to-treat cancers. Trials in this area include breast cancer, lung cancer, gastroesophageal cancer, gastric cancer, cervical cancer, and head and neck cancer, often aiming to improve survival, delay progression, or support treatment after surgery.

• Testing new cancer therapies for advanced and metastatic disease
• Studying treatment effectiveness in breast, lung, gastric, and cervical cancers
• Evaluating options that may improve disease-free and overall survival

Many of these trials are designed to compare promising immunotherapy, targeted therapy, and combination approaches against current standard care.

A major part of the site’s activity is centered on non-small cell lung cancer and small-cell lung cancer, including locally advanced, resectable, and metastatic disease. Research also covers biomarker-selected groups and patients whose disease has not responded to prior treatment, reflecting a strong interest in more personalized care for lung cancer.

• Improving treatment for NSCLC across different stages
• Studying therapies for small-cell lung cancer after chemoradiation
• Evaluating biomarker-guided approaches to match treatment more closely to tumor biology

These studies aim to test whether new immunotherapy and targeted combinations can better control disease and extend progression-free survival.

The site also conducts extensive research in breast cancer, including HER2-negative, HER2-low, hormone receptor-positive, and triple-negative breast cancer. Trials range from early-stage settings after surgery to metastatic disease, with a clear focus on reducing recurrence and improving long-term outcomes.

• Studying treatment after surgery in high-risk early breast cancer
• Evaluating new options for metastatic and recurrent breast cancer
• Comparing novel targeted and endocrine-based strategies with standard care

Researchers are especially interested in therapies that may strengthen disease control in patients with limited treatment options.

Clinical trials in hemic and lymphatic diseases include studies in multiple myeloma, myelofibrosis, acute lymphoblastic leukemia, and mantle cell lymphoma. The site is also involved in transplant-related research, including supportive and maintenance treatment around hematopoietic cell transplantation.

• Testing new approaches for relapsed or refractory blood cancers
• Assessing therapies for myelofibrosis and multiple myeloma
• Exploring supportive care around transplant and recovery

This work is aimed at improving both disease control and treatment tolerance in complex hematologic conditions.

Beyond the major disease groups, the site participates in studies of bladder cancer, urothelial carcinoma, renal cell carcinoma, ovarian cancer, colorectal cancer, esophageal cancer, and selected soft tissue sarcomas. There is also research into supportive care issues such as treatment-related skin toxicity.

• Evaluating new therapies for bladder, kidney, and urothelial cancers
• Studying treatment strategies for gastrointestinal cancers such as gastric, esophageal, and colorectal cancer
• Addressing symptom management and side effects linked to cancer therapy

These trials broaden the site’s oncology portfolio by combining disease-focused research with practical efforts to improve patient comfort during treatment.